Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Virus Res

Retrieve available abstracts of 134 articles:
HTML format



Single Articles


    September 2022
  1. BHAT S, Rishi P, Chadha VD
    Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches.
    Virus Res. 2022;318:198853.
    PubMed     Abstract available


  2. NUNES DBSM, Vieira C, Sa JM, Araujo GC, et al
    M2-2 gene as a new alternative molecular marker for phylogenetic, phylodynamic, and evolutionary studies of hRSV.
    Virus Res. 2022;318:198850.
    PubMed     Abstract available


  3. SHOKEEN K, Pandey S, Shah M, Kumar S, et al
    Insight towards the effect of the multi basic cleavage site of SARS-CoV-2 spike protein on cellular proteases.
    Virus Res. 2022;318:198845.
    PubMed     Abstract available


    August 2022
  4. FAYAD N, Habib WA, El-Shesheny R, Kandeil A, et al
    Lebanese SARS-CoV-2 genomics: 24 months of the pandemic.
    Virus Res. 2022;317:198824.
    PubMed     Abstract available


    July 2022
  5. MEISTER TL, Gottsauner JM, Schmidt B, Heinen N, et al
    Mouthrinses against SARS-CoV-2 - High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial.
    Virus Res. 2022;316:198791.
    PubMed     Abstract available


  6. ALCANTARA LCJ, Nogueira E, Shuab G, Tosta S, et al
    SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves.
    Virus Res. 2022;315:198785.
    PubMed     Abstract available


  7. DE AMARAL M, Ienes-Lima J
    Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.
    Virus Res. 2022;315:198769.
    PubMed     Abstract available


  8. GAIARSA S, Giardina F, Batisti Biffignandi G, Ferrari G, et al
    Comparative analysis of SARS-CoV-2 quasispecies in the upper and lower respiratory tract shows an ongoing evolution in the spike cleavage site.
    Virus Res. 2022;315:198786.
    PubMed     Abstract available


  9. SARKAR A, Paul S, Singh C, Chowdhury N, et al
    A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2.
    Virus Res. 2022;315:198768.
    PubMed     Abstract available


  10. BANSAL K, Kumar S
    Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant.
    Virus Res. 2022;315:198765.
    PubMed     Abstract available


    June 2022
  11. PAZ M, Aldunate F, Arce R, Ferreiro I, et al
    An evolutionary insight into Severe Acute Respiratory Syndrome Coronavirus 2 Omicron variant of concern.
    Virus Res. 2022;314:198753.
    PubMed     Abstract available


    May 2022
  12. YANG F, Zhu L, Liu F, Cheng L, et al
    Generation and characterization of monoclonal antibodies against the hemagglutinin of H3N2 influenza A viruses.
    Virus Res. 2022 May 17:198815. doi: 10.1016/j.virusres.2022.198815.
    PubMed     Abstract available


  13. MAITI AK
    Evolutionary shift from purifying selection towards divergent selection of SARS-CoV2 favors its invasion into multiple human organs.
    Virus Res. 2022;313:198712.
    PubMed     Abstract available


    April 2022
  14. ALMEIDA F, Santos LA, Trigueiro-Louro JM, RebelodeAndrade H, et al
    Optimization of A(H1N1)pdm09 vaccine seed viruses: the source of PB1 and HA vRNA as a major determinant for antigen yield.
    Virus Res. 2022 Apr 30:198795. doi: 10.1016/j.virusres.2022.198795.
    PubMed     Abstract available


  15. WEI N, Wang Q, Lin Z, Xu L, et al
    Systematic profiling of antigen bias in humoral response against SARS-CoV-2.
    Virus Res. 2022;312:198711.
    PubMed     Abstract available


  16. KOBAYASHI D, Hiono T, Ichii O, Nishihara S, et al
    Turkeys possess div6erse Siaalpha2-3Gal glycans that facilitate their dual susceptibility to avian influenza viruses isolated from ducks and chickens.
    Virus Res. 2022 Apr 13:198771. doi: 10.1016/j.virusres.2022.198771.
    PubMed     Abstract available


  17. GULARTE JS, da Silva MS, Mosena ACS, Demoliner M, et al
    Early introduction, dispersal and evolution of Delta SARS-CoV-2 in Southern Brazil, late predominance of AY.99.2 and AY.101 related lineages.
    Virus Res. 2022;311:198702.
    PubMed     Abstract available


  18. MIYAOKA Y, Yamaguchi M, Kadota C, Hasan MA, et al
    Rapid in vitro virucidal activity of slightly acidic hypochlorous acid water toward aerosolized coronavirus in simulated human-dispersed droplets.
    Virus Res. 2022;311:198701.
    PubMed     Abstract available


    March 2022
  19. ARBI M, Larbi I, Nsiri J, Behi IE, et al
    Inhibition of avian influenza virus H9N2 infection by antiviral hexapeptides that target viral attachment to epithelial cells.
    Virus Res. 2022;313:198745.
    PubMed     Abstract available


  20. GERDOL M, Dishnica K, Giorgetti A
    Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein.
    Virus Res. 2022;310:198674.
    PubMed     Abstract available


  21. MOHEBALI M, Hassanpour G, Zainali M, Gouya MM, et al
    SARS-CoV-2 in domestic cats (Felis catus) in the northwest of Iran: Evidence for SARS-CoV-2 circulating between human and cats.
    Virus Res. 2022;310:198673.
    PubMed     Abstract available


    February 2022
  22. DING XM, Wang YF, Lyu Y, Zou Y, et al
    The effect of influenza A (H1N1) pdm09 virus infection on cytokine production and gene expression in BV2 microglial cells.
    Virus Res. 2022 Feb 28:198716. doi: 10.1016/j.virusres.2022.198716.
    PubMed     Abstract available


    January 2022
  23. PERBOLIANACHIS P, Ferla D, Arce R, Ferreiro I, et al
    Phylogenetic analysis of SARS-CoV-2 viruses circulating in the South American region: genetic relations and vaccine strain match.
    Virus Res. 2022 Jan 21:198688. doi: 10.1016/j.virusres.2022.198688.
    PubMed     Abstract available


  24. SLAVOV SN, Bezerra RDS, Rodrigues ES, Santos EV, et al
    Genomic monitoring of the SARS-CoV-2 B1.1.7 (WHO VOC Alpha) in the Sao Paulo state, Brazil.
    Virus Res. 2022;308:198643.
    PubMed     Abstract available


  25. KUMAR S, Bansal K
    Cross-sectional genomic perspective of epidemic waves of SARS-CoV-2: A pan India study.
    Virus Res. 2022;308:198642.
    PubMed     Abstract available


  26. PAUL S, Bravo Vazquez LA, Reyes-Perez PR, Estrada-Meza C, et al
    The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review.
    Virus Res. 2022;308:198631.
    PubMed     Abstract available


  27. ALVAREZ-DIAZ DA, Laiton-Donato K, Torres-Garcia OA, Ruiz-Moreno HA, et al
    Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.
    Virus Res. 2022;308:198629.
    PubMed     Abstract available


  28. PRATHIVIRAJ R, Chellapandi P, Begum A, Kiran GS, et al
    Identification of genotypic variants and its proteomic mutations of Brazilian SARS-CoV-2 isolates.
    Virus Res. 2022;307:198618.
    PubMed     Abstract available


    December 2021
  29. YANG F, Dong D, Wu D, Zhu L, et al
    A multiplex real-time RT-PCR method for detecting H5, H7 and H9 subtype avian influenza viruses in field and clinical samples.
    Virus Res. 2021;309:198669.
    PubMed     Abstract available


  30. NISHIOKA K, Daidoji T, Nakaya T
    Downregulation of calcium-regulated heat stable protein 1 expression by low-temperature stimulation causes reduction of interferon-beta expression and sensitivity to influenza viral infection.
    Virus Res. 2021;309:198659.
    PubMed     Abstract available


  31. PORTER WT, Kelley EJ, Bowers JR, Engelthaler DM, et al
    Normalization of SARS-CoV-2 viral load via RT-qPCR provides higher-resolution data for comparison across time and between patients.
    Virus Res. 2021;306:198604.
    PubMed     Abstract available


    November 2021
  32. LEE TY, Lee H, Kim N, Jeon P, et al
    Comparison of SARS-CoV-2 variant lethality in human angiotensin-converting enzyme 2 transgenic mice.
    Virus Res. 2021;305:198563.
    PubMed     Abstract available


  33. WANG W, Li CP, He M, Li SW, et al
    The dominant strain of SARS-CoV-2 is a mosaicism.
    Virus Res. 2021;305:198553.
    PubMed     Abstract available


  34. BUKIN YS, Bondaryuk AN, Kulakova NV, Balakhonov SV, et al
    Phylogenetic reconstruction of the initial stages of the spread of the SARS-CoV-2 virus in the Eurasian and American continents by analyzing genomic data.
    Virus Res. 2021;305:198551.
    PubMed     Abstract available


  35. TAVAKOLI F, Izadi A, Yavarian J, Sharifi-Zarchi A, et al
    Determination of genetic characterization and circulation pattern of Respiratory Syncytial Virus (RSV) in children with a respiratory infection, Tehran, Iran, during 2018-2019.
    Virus Res. 2021;305:198564.
    PubMed     Abstract available


    October 2021
  36. FRANCESCHI VB, Ferrareze PAG, Zimerman RA, Cybis GB, et al
    Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021.
    Virus Res. 2021;304:198532.
    PubMed     Abstract available


  37. HUANG X, Zhang F, Zhu K, Lin W, et al
    dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation.
    Virus Res. 2021;304:198530.
    PubMed     Abstract available


  38. FORT H
    A very simple model to account for the rapid rise of the alpha variant of SARS-CoV-2 in several countries and the world.
    Virus Res. 2021;304:198531.
    PubMed     Abstract available


  39. VALE FF, Vitor JMB, Marques AT, Azevedo-Pereira JM, et al
    Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide.
    Virus Res. 2021;304:198526.
    PubMed     Abstract available


  40. ZHAO J, Wang L, Schank M, Dang X, et al
    SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects.
    Virus Res. 2021;304:198508.
    PubMed     Abstract available


  41. YAMAYA M, Deng X, Kikuchi A, Sugawara M, et al
    The proton ATPase inhibitor bafilomycin A1 reduces the release of rhinovirus C and cytokines from primary cultures of human nasal epithelial cells.
    Virus Res. 2021;304:198548.
    PubMed     Abstract available


  42. KHAN S, Dobrovolny HM
    A study of the effects of age on the dynamics of RSV in animal models.
    Virus Res. 2021;304:198524.
    PubMed     Abstract available


  43. KANNIAN P, Jayaraman BG, Alamelu S, Lavanya C, et al
    Implications in the quantification of SARS-CoV2 copies in concurrent nasopharyngeal swabs, whole mouth fluid and respiratory droplets.
    Virus Res. 2021;303:198442.
    PubMed     Abstract available


    September 2021
  44. YANG F, Xiao Y, Liu F, Yao H, et al
    Molecular Characterization and Antigenic analysis of reassortant H9N2 subtype avian influenza viruses in Eastern China in 2016.
    Virus Res. 2021 Sep 21:198577. doi: 10.1016/j.virusres.2021.198577.
    PubMed     Abstract available


  45. YE H, Bi Z, Fan W, Song S, et al
    Cellular hnRNPAB interacts with avian influenza viral protein PB2 and inhibits virus replication potentially by restricting PB2 mRNA nuclear export and PB2 protein level.
    Virus Res. 2021 Sep 20:198573. doi: 10.1016/j.virusres.2021.198573.
    PubMed     Abstract available


  46. HAQUE MFU, Bukhari SS, Ejaz R, Zaman FU, et al
    A novel RdRp-based colorimetric RT-LAMP assay for rapid and sensitive detection of SARS-CoV-2 in clinical and sewage samples from Pakistan.
    Virus Res. 2021;302:198484.
    PubMed     Abstract available


  47. GORAICHUK IV, Arefiev V, Stegniy BT, Gerilovych AP, et al
    Zoonotic and Reverse Zoonotic Transmissibility of SARS-CoV-2.
    Virus Res. 2021;302:198473.
    PubMed     Abstract available


  48. EMAM M, Oweda M, Antunes A, El-Hadidi M, et al
    Positive selection as a key player for SARS-CoV-2 pathogenicity: Insights into ORF1ab, S and E genes.
    Virus Res. 2021;302:198472.
    PubMed     Abstract available


  49. STEGMANN KM, Dickmanns A, Gerber S, Nikolova V, et al
    The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
    Virus Res. 2021;302:198469.
    PubMed     Abstract available


    August 2021
  50. BURNHAM AJ, Miller JR, Singh I, Billings EA, et al
    Novel isoforms of influenza virus PA-X and PB1-F2 indicated by automatic annotation.
    Virus Res. 2021 Aug 12:198545. doi: 10.1016/j.virusres.2021.198545.
    PubMed     Abstract available


  51. POLICARD M, Jain S, Rego S, Dakshanamurthy S, et al
    Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Virus Res. 2021;301:198464.
    PubMed     Abstract available


    July 2021
  52. TIAN X, Mo C, Zhou L, Yang Y, et al
    Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody.
    Virus Res. 2021;300:198445.
    PubMed     Abstract available


  53. HASSAN SS, Attrish D, Ghosh S, Choudhury PP, et al
    Pathogenic perspective of missense mutations of ORF3a protein of SARS-CoV-2.
    Virus Res. 2021;300:198441.
    PubMed     Abstract available


  54. ABBASI S, Hosseinkhan N, Shafiei Jandaghi NZ, Sadeghi K, et al
    Impact of human rhinoviruses on gene expression in pediatric patients with severe acute respiratory infection.
    Virus Res. 2021;300:198408.
    PubMed     Abstract available


  55. RODRIGUEZ T, Dobrovolny HM
    Quantifying the effect of trypsin and elastase on in vitro SARS-CoV infections.
    Virus Res. 2021;299:198423.
    PubMed     Abstract available


  56. SALEHI-VAZIRI M, Omrani MD, Pouriayevali MH, Fotouhi F, et al
    SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses.
    Virus Res. 2021;299:198421.
    PubMed     Abstract available


  57. ALTABLE M, de la Serna JM
    Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.
    Virus Res. 2021;299:198347.
    PubMed     Abstract available


    June 2021
  58. GHOSH N, Saha I, Sharma N, Nandi S, et al
    Genome-wide analysis of 10664 SARS-CoV-2 genomes to identify virus strains in 73 countries based on single nucleotide polymorphism.
    Virus Res. 2021;298:198401.
    PubMed     Abstract available


  59. DOERFLER W
    Viral Vector DNA- and RNA-Based SARS-CoV-2 Vaccines: Possible Integration into the Human Genome Are Adenoviral Genes Expressed in Vector-based Vaccines?
    Virus Res. 2021 Jun 1:198466. doi: 10.1016/j.virusres.2021.198466.
    PubMed     Abstract available


  60. LEI L, Qin H, Luo J, Tan Y, et al
    Construction and immunological evaluation of hepatitis B virus core virus-like particles containing multiple antigenic peptides of respiratory syncytial virus.
    Virus Res. 2021;298:198410.
    PubMed     Abstract available


    May 2021
  61. CARNEIRO DC, Sousa JD, Monteiro-Cunha JP
    The COVID-19 Vaccine Development: A Pandemic Paradigm.
    Virus Res. 2021 May 17:198454. doi: 10.1016/j.virusres.2021.198454.
    PubMed     Abstract available


  62. LEE S, Won D, Kim CK, Ahn J, et al
    Novel indel mutation in the N gene of SARS-CoV-2 clinical samples that were diagnosed positive in a commercial RT-PCR assay.
    Virus Res. 2021;297:198398.
    PubMed     Abstract available


  63. HASAN MM, Das R, Rasheduzzaman M, Hussain MH, et al
    Global and local mutations in Bangladeshi SARS-CoV-2 genomes.
    Virus Res. 2021;297:198390.
    PubMed     Abstract available


  64. RUIZ-GOMEZ X, Vazquez-Perez JA, Flores-Herrera O, Esparza-Perusquia M, et al
    Steady-state persistence of respiratory syncytial virus in a macrophage-like cell line and sequence analysis of the persistent viral genome.
    Virus Res. 2021;297:198367.
    PubMed     Abstract available


    April 2021
  65. FRANCISCO RDS JR, Benites LF, Lamarca AP, de Almeida LGP, et al
    Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil.
    Virus Res. 2021;296:198345.
    PubMed     Abstract available


  66. MIRANDA RL, Guterres A, de Azeredo Lima CH, Filho PN, et al
    Misinterpretation of viral load in COVID-19 clinical outcomes.
    Virus Res. 2021;296:198340.
    PubMed     Abstract available


  67. LI JY, Wang Q, Liao CH, Qiu Y, et al
    The 442th amino acid residue of the spike protein is critical for the adaptation to bat hosts for SARS-related coronaviruses.
    Virus Res. 2021;295:198307.
    PubMed     Abstract available


  68. SCAGNOLARI C, Pierangeli A, Frasca F, Bitossi C, et al
    Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19).
    Virus Res. 2021;295:198283.
    PubMed     Abstract available


  69. HU Z, Zhao J, Shi L, Hu J, et al
    Identification of the dominant non-neutralizing epitope in the haemagglutinin of H7N9 avian influenza virus.
    Virus Res. 2021;298:198409.
    PubMed     Abstract available


  70. NIYOMDECHA N, Suptawiwat O, Boonarkart C, Thitithanyanont A, et al
    Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication.
    Virus Res. 2021;295:198277.
    PubMed     Abstract available


    March 2021
  71. LANDGRAF G, Desheva YA, Rudenko LG
    Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines.
    Virus Res. 2021 Mar 17:198396. doi: 10.1016/j.virusres.2021.198396.
    PubMed     Abstract available


  72. MIYAOKA Y, Kabir H, Hasan A, Yamaguchi M, et al
    Virucidal activity of slightly acidic hypochlorous acid water toward influenza virus and coronavirus with tests simulating practical usage.
    Virus Res. 2021 Mar 8:198383. doi: 10.1016/j.virusres.2021.198383.
    PubMed     Abstract available


  73. SAFARI F, Afarid M, Rastegari B, Borhani-Haghighi A, et al
    CRISPR systems: Novel approaches for detection and combating COVID-19.
    Virus Res. 2021;294:198282.
    PubMed     Abstract available


  74. TAN J, Yuan Y, Xu C, Song C, et al
    A retrospective comparison of drugs against COVID-19.
    Virus Res. 2021;294:198262.
    PubMed     Abstract available


    February 2021
  75. KIM DH, Park BJ, Ahn HS, Go HJ, et al
    Canine interferon lambda 3 expressed using an adenoviral vector effectively induces antiviral activity against canine influenza virus.
    Virus Res. 2021 Feb 16:198342. doi: 10.1016/j.virusres.2021.198342.
    PubMed     Abstract available


  76. RIVERA-BAHENA GB, Marquez-Bandala AH, Lopez-Guerrero DV, Esquivel-Guadarrama FR, et al
    TGF-beta1 signaling inhibit the in vitro apoptotic, infection and stimulatory cell response induced by influenza H1N1 virus infection on A549 cells.
    Virus Res. 2021 Feb 10:198337. doi: 10.1016/j.virusres.2021.198337.
    PubMed     Abstract available


  77. LI B, Xiang G, He J, Li H, et al
    H7N9 influenza virus surveillance in Gansu, China in 2017.
    Virus Res. 2021 Feb 9:198335. doi: 10.1016/j.virusres.2021.198335.
    PubMed     Abstract available


  78. DE CONTO F, Conversano F, Razin SV, Belletti S, et al
    Host-cell dependent role of phosphorylated keratin 8 during influenza A/NWS/33 virus (H1N1) infection in mammalian cells.
    Virus Res. 2021 Feb 5:198333. doi: 10.1016/j.virusres.2021.198333.
    PubMed     Abstract available


  79. AKIYAMA Y, Sakashita K, Arihara M, Kimura Y, et al
    COVID-19 infection in Hokkaido, Japan might depend on the viscosity of atmospheric air.
    Virus Res. 2021;293:198259.
    PubMed     Abstract available


  80. ITO G, Morikawa M, Akimoto S, Masatani T, et al
    Establishment of a safe and convenient assay for detection of HA subtype-specific antibodies with PB2 gene-knockout influenza viruses.
    Virus Res. 2021 Feb 1:198331. doi: 10.1016/j.virusres.2021.198331.
    PubMed     Abstract available


    January 2021
  81. LUBAN J, Sattler RA, Muhlberger E, Graci JD, et al
    The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
    Virus Res. 2021;292:198246.
    PubMed     Abstract available


  82. KUMAR R, Rathi H, Haq A, Wimalawansa SJ, et al
    Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
    Virus Res. 2021;292:198235.
    PubMed     Abstract available


  83. JOONLASAK K, Batty EM, Kochakarn T, Panthan B, et al
    Genomic surveillance of SARS-CoV-2 in Thailand reveals mixed imported populations, a local lineage expansion and a virus with truncated ORF7a.
    Virus Res. 2021;292:198233.
    PubMed     Abstract available


  84. MALEK A, Hoque A
    Trends of 2019-nCoV in South Asian countries and prediction of the epidemic peaks.
    Virus Res. 2021;292:198230.
    PubMed     Abstract available


  85. CATTEL F, Giordano S, Bertiond C, Lupia T, et al
    Ozone therapy in COVID-19: A narrative review.
    Virus Res. 2021;291:198207.
    PubMed     Abstract available


  86. PIERETTI JC, Rubilar O, Weller RB, Tortella GR, et al
    Nitric oxide (NO) and nanoparticles - Potential small tools for the war against COVID-19 and other human coronavirus infections.
    Virus Res. 2021;291:198202.
    PubMed     Abstract available


  87. CABBAB ILN, Manalo RVM
    Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection.
    Virus Res. 2021;291:198190.
    PubMed     Abstract available


    December 2020
  88. TAHAGHOGHI-HAJGHORBANI S, Zafari P, Masoumi E, Rajabinejad M, et al
    The role of dysregulated immune responses in COVID-19 pathogenesis.
    Virus Res. 2020;290:198197.
    PubMed     Abstract available


  89. RAJEEV R, Prathiviraj R, Kiran GS, Selvin J, et al
    Zoonotic evolution and implications of microbiome in viral transmission and infection.
    Virus Res. 2020;290:198175.
    PubMed     Abstract available


  90. KILLICK R, Ballard C, Doherty P, Williams G, et al
    Transcription-based drug repurposing for COVID-19.
    Virus Res. 2020;290:198176.
    PubMed     Abstract available


  91. KHARE P, Sahu U, Pandey SC, Samant M, et al
    Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Virus Res. 2020;290:198169.
    PubMed     Abstract available


  92. FREIRE-PASPUEL B, Vega-Marino P, Velez A, Cruz M, et al
    "Sample pooling of RNA extracts to speed up SARS-CoV-2 diagnosis using CDC FDA EUA RT-qPCR kit".
    Virus Res. 2020;290:198173.
    PubMed     Abstract available


  93. YAMASAKI Y, Ooka S, Tsuchida T, Nakamura Y, et al
    The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide.
    Virus Res. 2020;290:198089.
    PubMed     Abstract available


    November 2020
  94. WEBER S, Ramirez C, Doerfler W
    Signal hotspot mutations in SARS-CoV-2 genomes evolve as the virus spreads and actively replicates in different parts of the world.
    Virus Res. 2020;289:198170.
    PubMed     Abstract available


  95. GADOTTI AC, de Castro Deus M, Telles JP, Wind R, et al
    IFN-gamma is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection.
    Virus Res. 2020;289:198171.
    PubMed     Abstract available


  96. RANGEL HR, Ortega JT, Maksoud S, Pujol FH, et al
    SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
    Virus Res. 2020;289:198154.
    PubMed     Abstract available


  97. ELHABYAN A, Elyaacoub S, Sanad E, Abukhadra A, et al
    The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review.
    Virus Res. 2020;289:198163.
    PubMed     Abstract available


  98. WANG X, Zheng J, Guo L, Yao H, et al
    Fecal viral shedding in COVID-19 patients: Clinical significance, viral load dynamics and survival analysis.
    Virus Res. 2020;289:198147.
    PubMed     Abstract available


  99. MARDANI R, Alamdary A, Mousavi Nasab SD, Gholami R, et al
    Association of vitamin D with the modulation of the disease severity in COVID-19.
    Virus Res. 2020;289:198148.
    PubMed     Abstract available


  100. CHOUDHARY S, Silakari O
    Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Virus Res. 2020;289:198146.
    PubMed     Abstract available


    October 2020
  101. ZHOU Y, Wu X, Yan D, Chen C, et al
    V292I Mutation in PB2 Polymerase Induces Increased Effects of E627K on Influenza H7N9 Virus Replication in Cells.
    Virus Res. 2020 Oct 16:198186. doi: 10.1016/j.virusres.2020.198186.
    PubMed     Abstract available


  102. YOKOYAMA Y, Briasoulis A, Takagi H, Kuno T, et al
    Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
    Virus Res. 2020;288:198137.
    PubMed     Abstract available


  103. ALI Z, Aman R, Mahas A, Rao GS, et al
    iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2.
    Virus Res. 2020;288:198129.
    PubMed     Abstract available


  104. DUTTA R, Buragohain L, Borah P
    Analysis of codon usage of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) and its adaptability in dog.
    Virus Res. 2020;288:198113.
    PubMed     Abstract available


  105. MOHAMMAD T, Shamsi A, Anwar S, Umair M, et al
    Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Virus Res. 2020;288:198102.
    PubMed     Abstract available


  106. SITARAS I, Spackman E, de Jong MCM, Parris DJ, et al
    Selection and Antigenic Characterization of Immune-Escape Mutants of H7N2 Low Pathogenic Avian Influenza Virus Using Homologous Polyclonal Sera.
    Virus Res. 2020 Oct 9:198188. doi: 10.1016/j.virusres.2020.198188.
    PubMed     Abstract available


  107. BAHRAMPOUR JUYBARI K, Pourhanifeh MH, Hosseinzadeh A, Hemati K, et al
    Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.
    Virus Res. 2020;287:198108.
    PubMed     Abstract available


  108. VAN DEN HOOGEN B, Santoni A, Sciume G, Bowie A, et al
    Immunometabolism pathways as the basis for innovative anti-viral strategies (INITIATE): A Marie Sklodowska-Curie innovative training network.
    Virus Res. 2020;287:198094.
    PubMed     Abstract available


  109. KESZEI Z, Vendrell XM, Soultsioti M, Molina PR, et al
    100 days of solitude: The spring of COVID-19 through the eyes of 15 young virologists of the INITIATE program.
    Virus Res. 2020;287:198093.
    PubMed    


  110. NIE Q, Li X, Chen W, Liu D, et al
    Phylogenetic and phylodynamic analyses of SARS-CoV-2.
    Virus Res. 2020;287:198098.
    PubMed     Abstract available


    September 2020
  111. AHLAWAT S, Asha, Sharma KK
    Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
    Virus Res. 2020;286:198103.
    PubMed     Abstract available


  112. LI C, Wang L, Ren L
    Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
    Virus Res. 2020;286:198073.
    PubMed     Abstract available


  113. MAGRO G
    COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
    Virus Res. 2020;286:198070.
    PubMed     Abstract available


  114. ROMEO A, Iacovelli F, Falconi M
    Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Virus Res. 2020;286:198068.
    PubMed     Abstract available


  115. PAN X, Dong L, Yang L, Chen D, et al
    Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
    Virus Res. 2020;286:198057.
    PubMed     Abstract available


  116. BEHLOUL N, Baha S, Shi R, Meng J, et al
    Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.
    Virus Res. 2020;286:198058.
    PubMed     Abstract available


  117. LI J, Wei X, Tian W, Zou J, et al
    Clinical features of discharged COVID-19 patients with an extended SARS-CoV-2 RNA positive signal in respiratory samples.
    Virus Res. 2020;286:198047.
    PubMed    


  118. LI J, Gong X, Wang Z, Chen R, et al
    Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China.
    Virus Res. 2020;286:198043.
    PubMed     Abstract available


  119. POST A, Dullaart RPF, Bakker SJL
    Sodium status and kidney involvement during COVID-19 infection.
    Virus Res. 2020;286:198034.
    PubMed     Abstract available


    August 2020
  120. SAMRAT SK, Tharappel AM, Li Z, Li H, et al
    Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
    Virus Res. 2020 Aug 23:198141. doi: 10.1016/j.virusres.2020.198141.
    PubMed     Abstract available


  121. WENJUN M
    Swine Influenza Virus: Current Status and Challenge.
    Virus Res. 2020 Aug 13:198118. doi: 10.1016/j.virusres.2020.198118.
    PubMed     Abstract available


  122. KAUR SP, Gupta V
    COVID-19 Vaccine: A comprehensive status report.
    Virus Res. 2020 Aug 12:198114. doi: 10.1016/j.virusres.2020.198114.
    PubMed     Abstract available


  123. DHAR D, Mohanty A
    Gut microbiota and Covid-19- possible link and implications.
    Virus Res. 2020;285:198018.
    PubMed     Abstract available


  124. ONAWOLE AT, Sulaiman KO, Kolapo TU, Akinde FO, et al
    COVID-19: CADD to the rescue.
    Virus Res. 2020;285:198022.
    PubMed     Abstract available


  125. ZHU X, Ge Y, Wu T, Zhao K, et al
    Co-infection with respiratory pathogens among COVID-2019 cases.
    Virus Res. 2020;285:198005.
    PubMed     Abstract available


  126. WANG Y, Song W, Zhao Z, Chen P, et al
    The impacts of viral inactivating methods on quantitative RT-PCR for COVID-19.
    Virus Res. 2020;285:197988.
    PubMed     Abstract available


    July 2020
  127. MANI JS, Johnson JB, Steel JC, Broszczak DA, et al
    Natural product-derived phytochemicals as potential agents against coronaviruses: A review.
    Virus Res. 2020;284:197989.
    PubMed     Abstract available


  128. ABUSALAMAH H, Reel JM, Lupfer CR
    Pyruvate Affects Inflammatory Responses of Macrophages During Influenza A Virus Infection.
    Virus Res. 2020 Jul 4:198088. doi: 10.1016/j.virusres.2020.198088.
    PubMed     Abstract available


  129. LIN L, Ting S, Yufei H, Wendong L, et al
    Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
    Virus Res. 2020 Jul 1:198082. doi: 10.1016/j.virusres.2020.198082.
    PubMed     Abstract available


    June 2020
  130. FANG A, Bi Z, Ye H, Yan L, et al
    SRSF10 inhibits the polymerase activity and replication of avian influenza virus by regulating the alternative splicing of chicken ANP32A.
    Virus Res. 2020 Jun 20:198063. doi: 10.1016/j.virusres.2020.198063.
    PubMed     Abstract available


    March 2020
  131. GODBOLE NM, Sinha RA, Tiwari S, Pawar SD, et al
    Analysis of influenza virus-induced perturbation in autophagic flux and its modulation during Vitamin D3 mediated anti-apoptotic signaling.
    Virus Res. 2020 Mar 28:197936. doi: 10.1016/j.virusres.2020.197936.
    PubMed     Abstract available


    January 2020
  132. ZHENG B, Zhou J, Wang H
    Host microRNAs and exosomes that modulate influenza virus infection.
    Virus Res. 2020 Jan 22:197885. doi: 10.1016/j.virusres.2020.197885.
    PubMed     Abstract available


    December 2019
  133. DE VRIES RD, Nieuwkoop NJ, Krammer F, Hu B, et al
    Analysis Of The Vaccine-Induced Influenza B Virus Hemagglutinin-Specific Antibody Dependent Cellular Cytotoxicity Response.
    Virus Res. 2019 Dec 11:197839. doi: 10.1016/j.virusres.2019.197839.
    PubMed     Abstract available


    October 2019
  134. LIU Y, Xie W, Chi M, Wen H, et al
    Mutations in the HRB linker of Human Parainfluenza Virus Type 3 Fusion Protein Reveal its Importance for Fusion Activity.
    Virus Res. 2019 Oct 16:197791. doi: 10.1016/j.virusres.2019.197791.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: